

DAFTAR PUSTAKA

- Aaftab, G.P., Patil, A.B., & Medegar, S. (2020). Multivariate analysis of risk factors for ESBL and AmpC producing *Escherichia coli* and *Klebsiella pneumoniae* at a Tertiary Care Hospital in Karnataka: A case control study. *Indian J. Microbiol. Res.* 5 : 1–6.
- Adriaenssens, N., Bruyndonckx, R., Versporten, A., Hens, N., Monnet, D.L., Molenberghs, G., *et al.* (2021). Consumption of quinolones in the community, European Union/European Economic Area, 1997-2017. *J. Antimicrob. Chemother.* 76 : II37–II44.
- Akhter, S. (2015). Prevalence and Detection of AmpC β -Lactamases in Gram Negative Bacilli from BIHS Hospital, Mirpur, Dhaka. *Int. J. Res. Stud. Microbiol. Biotechnol.* 1 : 1–6.
- Al-Hazmi, H. (2015). Role of duration of catheterization and length of hospital stay on the rate of catheter-related hospital-acquired urinary tract infections. *Res. Reports Urol.* 7 : 41–47.
- Al Lawati, H., Blair, B.M., & Larnard, J. (2024). Urinary Tract Infections: Core Curriculum 2024. *Am. J. Kidney Dis.* 83 : 90–100.
- Alghoraibi, H., Asidan, A., Aljawaied, R., Almukhayzim, R., Alsaydan, A., Alamer, E., *et al.* (2023). Recurrent Urinary Tract Infection in Adult Patients, Risk Factors, and Efficacy of Low Dose Prophylactic Antibiotics Therapy. *J. Epidemiol. Glob. Health* 13 : 200–211.
- Almas, S., Carpenter, R.E., Rowan, C., Tamrakar, V.K., Bishop, J., & Sharma, R. (2023). Advantage of precision metagenomics for urinary tract infection diagnostics. *Front. Cell. Infect. Microbiol.* 13 : 1–11.
- Ambite, I., Butler, D., Wan, M.L.Y., Rosenblad, T., Tran, T.H., Chao, S.M., *et al.* (2021). Molecular determinants of disease severity in urinary tract infection. *Nat. Rev. Urol.* 18 : 468–486.
- Anonim (2022). Improving the use of antibiotics with the AWaRe book, in: Zanichelli, V., Huttner, B., Cappello, B., & Moja, L. (Eds.), *The WHO AWaRe (Access, Watch, Reserve) Antibiotic Book*. pp. 5–10.
- Armbruster, C.E., Mobley, H.L.T., & Pearson, M.M. (2018). Pathogenesis of *Proteus mirabilis* Infection. *EcoSal Plus.* 8 : 1–123.
- Aryal, S.C., Upreti, M.K., Sah, A.K., Ansari, M., Nepal, K., Dhungel, B., *et al.* (2020). Plasmid-mediated AMPC β-lactamase CITM and DHAM genes among gram-negative clinical isolates. *Infect. Drug Resist.* 13 : 4249–4261.
- Bala, R., Singh, V.A., Gupta, N., & Rakshit, P. (2020). Prevalence, multidrug-resistance and risk factors for AmpC β-lactamases producing *Escherichia coli* from hospitalized patients. *J. Infect. Dev. Ctries.* 14 : 1466–1469.
- Basavaraju, M., & Gunashree, B.S. (2023). *Escherichia coli* : An Overview of Main Characteristics, IntechOpen. Available at: <http://dx.doi.org/10.5772/intechopen.105508> diakses pada tanggal 13 Maret 2024.
- Bonomo, R.A. (2017). β-Lactamases: A Focus on Current Challenges. *Cold Spring Harb. Perspectives Med.* 7 : 1–15.
- Burnham, J.P., & Kollef, M.H. (2018). qSOFA score: Predictive validity in

- Enterobacteriaceae bloodstream infections. *J. Crit. Care* 43 : 143–147.
- Bush, N.G., Diez-Santos, I., Sankara Krishna, P., Clavijo, B., & Maxwell, A. (2025). Insights into antibiotic resistance promoted by quinolone exposure. *Antimicrob. Agents Chemother.* 69 : e0099724.
- Carcione, D., Siracusa, C., Sulejmani, A., Leoni, V., & Intra, J. (2021). Old and new beta-lactamase inhibitors: Molecular structure, mechanism of action and clinical use. *Antibiotics* 10 : 1–14.
- Carsiti, Dian, W., & Indrawati, R. (2023). Lama Hari Rawat Pasien Coronary Artery Bypass Graft (CABG). *J. Hosp. Manag. ISSN* 6 : 2615–8337.
- Cheung, D.A., Nicholson, A., Butterfield, T.R., & DaCosta, M. (2020). Prevalence, co-infection and antibiotic resistance of *Escherichia coli* from blood and urine samples at a hospital in Jamaica. *J. Infect. Dev. Ctries.* 14 : 146–152.
- Ching, C., Schwartz, L., Spencer, J.D., & Becknell, B. (2021). Innate immunity and urinary tract infection. *Pediatr Nephrol.* 35 : 1183–1192.
- Cristina, A., Oliveira, E.A., & Mak, R.H. (2020). Urinary tract infection in pediatrics : an overview. *J. Pediatr.* 96 : 65–79.
- D'Angelo, R.G., Johnson, J.K., Bork, J.T., & Heil, E.L. (2016). Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria. *Expert Opin. Pharmacother.* 17 : 953–967.
- Dahesihdewi, A., El Khair, R., Purwaningtyastuti, E., Puspawati, Y., & Marwati, Y. (2022). Antibiotogram Patogen Pasien Bahan Urin Tahun 2022, in: Hartanto, H.S. (Ed.), *Pola Mikroba Dan Antibiotogram Tahun 2022*. pp. 69, 298.
- Dahlan, M.S. (2013). Menggunakan Rumus Besar Sampel Secara Benar, in: Suslia, A. (Ed.), *Besar Sampel Dan Cara Pengambilan Sampel Dalam Penelitian Kedokteran Dan Kesehatan*. pp. 35–60.
- Dickson, K., Zhou, J., & Lehmann, C. (2024). Lower Urinary Tract Inflammation and Infection: Key Microbiological and Immunological Aspects. *J. Clin. Med.* 13 : 1–25.
- Dolmatova, E. V., Wang, K., Mandavilli, R., & Griendling, K.K. (2021). The effects of sepsis on endothelium and clinical implications. *Cardiovasc. Res.* 117 : 60–73.
- Etemadi, S., Ebrahimzadeh Leylabadlo, H., & Ghotaslou, R. (2020). AmpC β -lactamase among Enterobacteriaceae: A new insight. *Gene Reports* 19 : 1–6.
- Fadrian (2023). Resistensi Antibiotik, in: Fadrian (Ed.), *Antibiotik, Infeksi, Dan Resistensi*. pp. 15–22.
- Fauziyah, N. (2019). Perhitungan Besar Sampel, in: Pramintarto, G. (Ed.), *Sampling Dan Besar Sampel Bidang Kesehatan Masyarakat Dan Klinis*. pp. 15–20.
- Firman, F. (2024). Analisis Pembiayaan berdasarkan Lama Rawat Pasien BPJS Diabetes Melitus Tipe II Komplikasi Sirkulasi Perifer di RSUD Muhammadiyah Bantul. *J. Ekon. Kesehat. Indones.* 9 : 40–50.
- Flores-Mireles, A.L., Walker, J.N., Caparon, M., & Hultgren, S.J. (2015). Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nat Rev Microbiol* 13 : 269–284.
- Ghotaslou, R., Sadeghi, M.R., Akhi, M.T., Hasani, A., & Asgharzadeh, M. (2018). Prevalence and antimicrobial susceptibility patterns of ESBL, ampC and

- carbapenemase-producing enterobacteriaceae isolated from hospitalized patients in Azerbaijan, Iran. *Iran. J. Pharm. Res.* 17 : 79–88.
- Gokhale, S., Taylor, D., Gill, J., Hu, Y., Zeps, N., Lequertier, V., *et al.* (2023). Hospital length of stay prediction tools for all hospital admissions and general medicine populations: systematic review and meta-analysis. *Front. Med.* 10 : 1–15.
- Gude, M.J., Seral, C., Sáenz, Y., González-Domínguez, M., Torres, C., & Castillo, F.J. (2012). Evaluation of four phenotypic methods to detect plasmid-mediated AmpC β -lactamases in clinical isolates. *Eur. J. Clin. Microbiol. Infect. Dis.* 31 : 2037–2043.
- Guliciuc, M., Maier, A.C., Maier, I.M., Kraft, A., Cucuruzac, R.R., Rebegea, L., *et al.* (2021). The Urosepsis — A Literature Review. *Medicina.* 57 : 1–11.
- Gupta, G., Tak, V., & Mathur, P. (2014). Detection of AmpC β Lactamases in Gram-negative Bacteria. *J. Lab. Physicians* 6 : 001–006.
- Hafsan (2014). Ruang Lingkup Mikrobiologi Analitik, in: Nur, F. (Ed.), *Mikrobiologi Analitik*. pp. 1–5.
- Hassan, A., Usman, J., Kaleem, F., Gill, M.M., Khalid, A., Iqbal, M., *et al.* (2013). Evaluation of Different Phenotypic Methods for Detection of Amp C Beta-Lactamase Producing Bacteria in Clinical Isolates. *J. Coll. Physicians Surg. Pakistan* 23 : 629–632.
- Herrmann, J., Burgener-Gasser, A.V., Goldenberger, D., Roth, J., Weisser, M., Tamma, P.D., *et al.* (2024). Cefepime versus carbapenems for treatment of AmpC beta-lactamase-producing Enterobacterales bloodstream infections. *Eur. J. Clin. Microbiol. Infect. Dis.* 43 : 213–221.
- Hidayati, S.N. (2016). PERTUMBUHAN Escherichia coli YANG DIISOLASI DARI FESES ANAK AYAM BROILER TERHADAP EKSTRAK DAUN SALAM (*Syzygium polyanthum* [Wight.] Walp.). *J. Med. Vet.* 10 : 2007–2010.
- Hotchkiss, R.S., Moldawer, L.L., Opal, S.M., Reinhart, K., Turnbull, I.R., & Department, J.-L.V. (2017). Sepsis and septic shock. *Nat Rev Dis Prim.* 176 : 139–148.
- Inamdar, D.P., & B, A. (2020). Phenotypic methods for detection of Amp C β lactamases in Gram negative clinical isolates of a tertiary care hospital. *Indian J. Microbiol. Res.* 7 : 125–129.
- Jenkins, C., Rentenaar, R.J., Landraud, L., & Brisse, S. (2017). Enterobacteriaceae. In: Infectious Diseases, in: *Infectious Disease (Fourth Edition)*. pp. 1565–1578.e2.
- Jensen, B.H., Olsen, K.E.P., Struve, C., Krogfelt, K.A., & Petersen, A.M. (2014). Epidemiology and clinical manifestations of enteroaggregative escherichia coli. *Clin. Microbiol. Rev.* 27 : 614–630.
- Joji, R., Al-Mahameed, A., Jishi, T., Fatani, D., Saeed, N., Jaradat, A., *et al.* (2021). Molecular detection of plasmid-derived AmpC β -lactamase among clinical strains of Enterobacteriaceae in Bahrain. *Ann. Thorac. Med.* 16 : 287–293.
- Joya, M., Aalemi, A.K., & Baryali, A.T. (2022). Prevalence and Antibiotic Susceptibility of the Common Bacterial Uropathogen Among UTI Patients in French Medical Institute for Children. *Infect. Drug Resist.* 15 : 4291–4297.

- Kadariswantiningsih, I.N., Rampengan, D.D., Ramadhan, R.N., Idrisova, A., Idrisov, B., & Empitu, M.A. (2025). Antibiotic resistance in Indonesia: A systematic review and meta-analysis of extended-spectrum beta-lactamase-producing bacteria (2008–2024). *Trop. Med. Int. Heal.* 30 : 246–259.
- Kamel, F.H., & Jarjes, S.F. (2015). Gram-negative bacilli bacteria, in: Kamel, F.H., & Jarjes, S.F. (Eds.), *Essentials of Bacteriology and Immunology*. pp. 156–181.
- Kolesnyk, A.S., & Khairova, N.F. (2022). Justification for the Use of Cohen's Kappa Statistic in Experimental Studies of NLP and Text Mining. *Cybern. Syst. Anal.* 58 : 280–288.
- Kranz, J., Schmidt, S., Wagenlehner, F., & Schneidewind, L. (2020). Catheter-Associated Urinary Tract Infections in Adult Patients Preventive Strategies and Treatment Options. *Dtsch. Arztebl. Int.* 117 : 83–90.
- Kurniawan, R., Darniati, D., Abrar, M., Fakhurrazi, F., Jalaluddin, M., & Erina, E. (2023). Isolasi dan Identifikasi Bakteri Eschericia Coli Pada Produk Ceker Ayam Bakar Di Gampong Ulee Lheue Kota Banda Aceh. *J. Ilm. Mhs. Vet.* 7 : 2–9.
- Laih, C.Y., Hsiao, P.J., Hsieh, P.F., Wang, Y. De, Lai, C.M., Yang, C.T., *et al.* (2022). QSOFA and SOFA scores are valuable tools for predicting postoperative sepsis resulting from ureteroscopic lithotripsy (URSL). *Medicine (Baltimore)*. 101 : 1–6.
- Lambden, S., Laterre, P.F., Levy, M.M., & Francois, B. (2019). The SOFA score - Development, utility and challenges of accurate assessment in clinical trials. *Crit. Care* 23 : 1–9.
- Li, X., Chen, Y., Gao, W., Ye, H., Shen, Z., Wen, Z., *et al.* (2017). A 6-year study of complicated urinary tract infections in Southern China: Prevalence, antibiotic resistance, clinical and economic outcomes. *Ther. Clin. Risk Manag.* 13 : 1479–1487.
- Lim, C.L., & Spelman, D. (2019). Mortality impact of empirical antimicrobial therapy in ESBL- and AmpC-producing Enterobacteriaceae bacteremia in an Australian tertiary hospital. *Infect. Dis. Heal.* 24 : 124–133.
- Linciano, P., Vicario, M., Kekez, I., Bellio, P., Celenza, G., Martín-Bleuca, I., *et al.* (2019). Phenylboronic acids probing molecular recognition against class A and class C β -lactamases. *Antibiotics* 8 : 1–15.
- Liu, H.Y., Prentice, E.L., & Webber, M.A. (2024). Mechanisms of antimicrobial resistance in biofilms. *npj Antimicrob. Resist.* 2 : 1–10.
- Mansouri, S., Savari, M., Malakian, A., & Abbasi Montazeri, E. (2024). High prevalence of multidrug-resistant Enterobacterales carrying extended-spectrum beta-lactamase and AmpC genes isolated from neonatal sepsis in Ahvaz, Iran. *BMC Microbiol.* 24 : 1–11.
- Manyahi, J., Kibwana, U., Mgimba, E., & Majigo, M. (2020). Multi-drug resistant bacteria predict mortality in bloodstream infection in a tertiary setting in Tanzania. *PLoS One* 15 : 1–11.
- Mazeraud, A., Righy, C., Bouchereau, E., & Benghanem, S. (2020). Septic-Associated Encephalopathy : a Comprehensive Review. *Neurotherapeutics* 17 : 392–403.

- Meini, S., Tascini, C., Cei, M., Sozio, E., & Rossolini, G.M. (2019). AmpC β -lactamase-producing Enterobacterales: what a clinician should know. *Infection* 47 : 363–375.
- Mol P, R., Bindayna, K.M., & Shanthi, G. (2021). Evaluation of Two Phenotypic Methods for the Detection of Plasmid-Mediated AmpC β -Lactamases among Enterobacteriaceae Isolates. *J. Lab. Physicians* 13 : 151–155.
- Mounier, R., Le Guen, R., Woerther, P.-L., Nacher, M., Bonnefon, C., Mongardon, N., *et al.* (2022). Clinical outcome of wild-type AmpC-producing Enterobacterales infection in critically ill patients treated with β -lactams.pdf. *Ann. Intensive Care* 12 : 1–10.
- Najjuka, C.F., Kateete, D.P., Lodiongo, D.K., Mambo, O., Mocktar, C., Kayondo, W., *et al.* (2020). Prevalence of plasmid-mediated AmpC beta-lactamases in Enterobacteria isolated from urban and rural folks in Uganda. *AAS Open Res.* 3 : 1–17.
- Najmah, Ridwan, A., Idayanti, T., Emelda, Setianingtyas, D., Dwijastuti, N.M.S., *et al.* (2024). Prinsip-Prinsip Sterilisasi Medium dan Teknik Isolasi Bakteri, in: Nurlila, R.U., & Malik, N. (Eds.), *Pengantar Mikrobiologi*. pp. 17–44.
- Ning, Q., Chen, T., Wang, G., Xu, D., Yu, Yanyan, Mao, Q., *et al.* (2022). Expert Consensus on Diagnosis and Treatment of End-Stage Liver Disease Complicated with Infections. *Infect. Dis. Immun.* 2 : 168–178.
- Partridge, S.R. (2015). Resistance mechanisms in Enterobacteriaceae. *Pathology* 47 : 276–284.
- Perera, P.D.V.M., Gamage, S., De Silva, H.S.M., Jayatilleke, S.K., de Silva, N., Aydin, A., *et al.* (2022). Phenotypic and genotypic distribution of ESBL, AmpC β -lactamase and carbapenemase-producing Enterobacteriaceae in community-acquired and hospital-acquired urinary tract infections in Sri Lanka. *J. Glob. Antimicrob. Resist.* 30 : 115–122.
- Poignant, S., Guinard, J., Guigon, A., Bret, L., Poisson, D.M., Boulain, T., *et al.* (2016). Risk factors and outcomes for intestinal carriage of AmpC-hyperproducing Enterobacteriaceae in intensive care unit patients. *Antimicrob. Agents Chemother.* 60 : 1883–1887.
- Pospišil, M., Car, H., & Elve, V. (2023). Bloodstream Infections by AmpC-Producing Enterobacterales: Risk Factors and Therapeutic Outcome. *Pathogens* 12 : 1–15.
- Rawy, D.K., El-Mokhtar, M.A., Hemida, S.K., Askora, A., & Yousef, N. (2020). Isolation, Characterization and Identification of Klebsiella Pneumoniae From Assiut University Hospital and Sewage Water in Assiut Governorate, Egypt. *Assiut Univ. J. Bot. Microbiol.* 49 : 60–76.
- Riley, L.W. (2020). Distinguishing Pathovars from Nonpathovars: Escherichia coli. *Microbiol. Spectr.* 8 : 1–23.
- Robotjazi, S., Nikkhahi, F., Niazadeh, M., Amin Marashi, S.M., Peymani, A., Javadi, A., *et al.* (2021). Phenotypic Identification and Genotypic Characterization of Plasmid-Mediated AmpC β -Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Isolates in Iran. *Curr. Microbiol.* 78 : 2317–2323.
- Salvia, T., Dolma, K.G., Dhakal, O.P., Khandelwal, B., & Singh, L.S. (2022).

- Phenotypic Detection of ESBL, AmpC, MBL, and Their Co-occurrence among MDR Enterobacteriaceae Isolates. *J. Lab. Physicians* 14 : 329–335.
- Santiago, G.S., Gonçalves, D., da Silva Coelho, I., de Mattos de Oliveira Coelho, S., & Neto Ferreira, H. (2020). Conjugative plasmidic AmpC detected in *Escherichia coli*, *Proteus mirabilis* and *Klebsiella pneumoniae* human clinical isolates from Portugal. *Brazilian J. Microbiol.* 51 : 1807–1812.
- Schaffer, J.N., & Pearson, M.M. (2015). *Proteus mirabilis* and Urinary Tract Infections. *Microbiol Spectr* 3 : 212–263.
- Shaaban, M., Elshaer, S.L., & Abd El-Rahman, O.A. (2022). Prevalence of extended-spectrum β -lactamases, AmpC, and carbapenemases in *Proteus mirabilis* clinical isolates. *BMC Microbiol.* 22 : 1–13.
- Shagufta, R., Fomda, B., Gulnaz, B., Lubna, S., Jan, A., Mohd, S., *et al.* (2017). Prevalence of AmpC Beta-lactamase in Gram Negative Bacilli by Different Phenotypic Methods in a Tertiary Care Institute in Kashmir. *Br. J. Med. Med. Res.* 19 : 1–9.
- Shawky, S.M., Abdallah, A., & Khouly, M. (2015). Antimicrobial activity of colistin and tiegacycline against carbapenem-resistant *Klebsiella pneumoniae* clinical isolates in Alexandria, Egypt. *Int. J. Curr. Microbiol. Appl. Sci.* 4 : 731–742.
- Silva, A.S.D.N., da Silva, N.C.Z., Do Valle, F.M., da Rocha, J.A., Ehrlich, S., & Martins, I.S. (2024). Mortality and Risk Factors of Death in Patients with AmpC β -Lactamase Producing Enterobacterales Bloodstream Infection: A Cohort Study. *Infect. Drug Resist.* 17 : 4023–4035.
- Sime, W.T., Biazin, H., Zeleke, T.A., & Desalegn, Z. (2020). Urinary tract infection in cancer patients and antimicrobial susceptibility of isolates in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. *PLoS One* 15 : 1–10.
- Stone, K., Zwiggelaar, R., Jones, P., & Parthaláin, N. Mac (2022). A systematic review of the prediction of hospital length of stay: Towards a unified framework. *PLOS Digit. Heal.* 1 : 1–38.
- Sujith, S., Solomon, A.P., & Rayappan, J.B.B. (2024). Comprehensive insights into UTIs: from pathophysiology to precision diagnosis and management. *Front. Cell. Infect. Microbiol.* 14 : 1–27.
- Sultan, A.M., Gouda, N.S., Eldegl, H.E., Sultan, M.A., Nabeeh, M.M., & Nomir, M.M. (2019). Healthcare Associated Infections Caused by Gram-negative Bacilli in Adult Intensive Care Units: Identification of AmpC Beta-Lactamases Mediated Antimicrobial Resistance. *Egypt. J. Med. Microbiol.* 28 : 61–68.
- Tamma, P.D., Doi, Y., Bonomo, R.A., Johnson, J.K., & Simner, P.J. (2019). A Primer on AmpC β -Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World. *Clin. Infect. Dis.* 69 : 1446–1455.
- Tebano, G., Zaghi, I., Cricca, M., & Cristini, F. (2024). Antibiotic treatment of infections caused by AmpC-Producing Enterobacterales. *Pharmacy* 12 : 1–17.
- Tian, X., Sun, S., Jia, X., Zou, H., Li, S., & Zhang, L. (2018). Epidemiology of and risk factors for infection with extended-spectrum β -lactamase-producing carbapenem-resistant enterobacteriaceae: Results of a double case–control study. *Infect. Drug Resist.* 11 : 1339–1346.

- Ting, S.M.V., Ismail, Z., & Hanafiah, A. (2024). Prevalence of AmpC beta-lactamase and extended spectrum beta-lactamase co-producer in *Escherichia coli* and *Klebsiella* species in a teaching hospital. *Malays. J. Pathol.* 46 : 79–89.
- Tocut, M., Zohar, I., Schwartz, O., Yossepowitch, O., & Maor, Y. (2022). Short- and long-term mortality in patients with urosepsis caused by *Escherichia coli* susceptible and resistant to 3rd generation cephalosporins. *BMC Infect. Dis.* 22 : 1–9.
- Tolani, M.A., Suleiman, A., Awaisu, M., Abdulaziz, M.M., Lawal, A.T., & Bello, A. (2020). Acute urinary tract infection in patients with underlying benign prostatic hyperplasia and prostate cancer. *Pan Afr. Med. J.* 36 : 1–9.
- Utamy, G., Hasbi, M., & Purwanto, E. (2021). Isolasi dan Identifikasi Bakteri Penghasil Biosurfaktan pada Kolam Anaerob IPAL Industri Minyak Sawit. *Sumberd. dan Lingkungan. Akuatik* 2 : 231–240.
- Wanke-Rytt, M., Sobierajski, T., Lachowicz, D., Seliga-Gąsior, D., & Podsiadły, E. (2023). Analysis of Etiology of Community-Acquired and Nosocomial Urinary Tract Infections and Antibiotic Resistance of Isolated Strains: Results of a 3-Year Surveillance (2020–2022) at the Pediatric Teaching Hospital in Warsaw. *Microorganisms* 11 : 1–13.
- Wassef, M., Behiry, I., Younan, M., Guindy, N. El, Mostafa, S., & Abada, E. (2014). Genotypic identification of AmpC β -lactamases production in gram-negative Bacilli isolates. *Jundishapur J. Microbiol.* 7 : 1–8.
- Zhou, Y., Zhou, Z., Zheng, L., Gong, Z., Li, Y., Jin, Y., *et al.* (2023). Urinary Tract Infections Caused by Uropathogenic *Escherichia coli*: Mechanisms of Infection and Treatment Options. *Int. J. Mol. Sci.* 24 : 1–33.